Search Results for “FDA” – Page 166 – media

Plunging HIV Infections Linked to Increased U.S. PrEP use

Pre-exposure prophylaxis (PrEP) by U.S. residents against HIV infection has resulted in positive outcomes. Incidence of new HIV infections among those 13 years old and above fell during 2012 - 2016, and this plunge presented a statistically noteworthy association with an increase in drug prophylaxis among U.S. residents in the same duration.
- Source: MDEdge
- 705
- August 11, 2018
HIV Researches
One Boy’s Struggle with Epilepsy Leads to First Marijuana-Derived Medicine

Epidiolex, compounded from decontaminated cannabidiol, or CBD, permitted for two atypical types of epilepsy, would be the first prescription medication extracted from the marijuana plant, expected to reach pharmacies this fall.
- Source: NPR
- 719
- August 9, 2018
FDA Medical marijuana New Approvals
Efficiency and Reliability of Clinical Laboratory & Analytical Equipment -The Medical Analyst and Truth Teller

In the medical field, no matter what kind of science or technological issue we are dealing with, laboratory equipment is essential for all researching, experimenting and measuring processes, hence, the efficiency and reliability of the laboratory equipment are to key the indexes we need to focus on.
- Source: Ddu
- 840
- August 7, 2018
medical device products Researches
Sun Pharma Launches Kapspargo Sprinkle to Treat Chest Pain & High Blood Pressure

Sun Pharma, India’s largest drugmaker, has launched Kapspargo Sprinkle in the US. This drug is used in the treatment of heart failure, chest pain, and high blood pressure.
- Source: MoneyControl
- 585
- August 7, 2018
beta blocker FDA New Approvals
Avatrombopag Reduced Procedure-Related Transfusions in Thrombocytopenia, Chronic Liver Disease Patients

Findings from two international, randomized, double-blind, phase III, placebo-controlled trials published in the September issue of Gastroenterology revealed that the oral second-generation thrombopoietin agonist avatrombopag (Doptelet) when given once a day, notably decreased the requirement for platelet transfusion...
- Source: MDEdge
- 936
- August 3, 2018
chronic liver disease Clinical Trials FDA
Aerie Extends Drug-Delivery Tech Contract with DSM Biomedical

The extended deal with DSM offers Aerie an elite worldwide license to DSM’s polyesteramide polymer technology for a limitless number of drugs in any ophthalmic indication and also an exposure to DSM’s preclinical latanoprost implant created for people with glaucoma. The two companies have spanned their partnership till the end of 2020, as per Aerie.
- Source: DrugDeliveryBusiness
- 1,005
- August 3, 2018
Company Insight digital health glaucoma pharmaceutical
$7.6M Granted to SkinVision to Expand Skin Cancer App

$7.6 million has been granted to SkinVision, an Amsterdam-based skin cancer screening app, as backing from active investors Leo Pharma and PHS Fund, with supplementary aid from unnamed new sponsors which the company called "high net worth impact investors."
- Source: MobiHealthNews
- 779
- August 2, 2018
Market Views mHealth skin cancer
Experimental Drug to Treat Alzheimer Disease

The condition of memory loss is termed as Alzheimer’s disease, affecting more than 5 million people and there is still no definite cure. A research team reported that an experimental drug could treat Alzheimer’s disease by slowing down the process of clear thinking and memory.
- Source: NBCNews
- 692
- August 1, 2018
Alzheimer's disease Researches
Bayer Sidelines Essure Concerns as Anecdotal, Legal Claims Build Up

A week post Bayer’s announcement on the withdrawal of Essure, its contraceptive implant from the market by this year-end due to inadequate sales, its clinical safety is questioned as consumer and legal stress builds up concerning complaints of extreme fatigue, pain and bleeding.
- Source: FierceBiotech
- 527
- July 30, 2018
Bayer Company Insight contraceptive device Essure
Monoclonal Antibody Delays Cognitive Decline, Erases Alzheimer’s Plaques in Phase 2 Trial

A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
- Source: MDEdge
- 957
- July 30, 2018
Alzheimer's disease Clinical Trials FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.